UK's NICE approves Janssen's Invokana for type 2 diabetes

25 June 2014
nhs-big

The UK’s National Institute for Health and Care Excellence (NICE) has issued new final guidance recommending Invokana (canagliflozin), from US health care giant Johnson & Johnson’s (NYSE: JNJ) subsidiary Janssen-Cilag, for treating some people with type 2 diabetes.

Canagliflozin also has the additional benefits of modest weight loss (2%-4%) and blood pressure reduction (although it is not licensed for use in weight loss or blood pressure reduction). NICE recommends canagliflozin to be used as a treatment for adults with type 2 diabetes, as either dual therapy in combination with metformin, only if a sulfonylurea is contraindicated or not tolerated, or where the person is at significant risk of hypoglycemia or its consequences; as triple therapy in combination with metformin and a sulfonylurea, or metformin and thiazolidinedione; or in combination with insulin with or without other anti-diabetic therapies.

“Securing positive NICE Guidance is an important milestone for canagliflozin. Janssen is pleased that people with type 2 diabetes will now have access to a new treatment option to help them control their blood sugar levels,” said Peter Barnes, medical director at Janssen UK.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical